Saturday 17 October 2026
Export ALZN’s income statement to Excel — free account
Alzamend Neuro, Inc.
ALZN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 46.9% and free cash flow grew 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.32
0.04
+3.13%
Follow ALZN
| Dec '18 | Apr '19 | Dec '19 | Apr '20 | Apr '21 | Apr '22 | Apr '23 | Apr '24 | Apr '25 | Apr '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.27 | 1.27 | — | 1.83 | 3.24 | 12.37 | 2.03 | 0.14 | 6.58 | 1.31 |
Net Debt/EBITDA |
0.01 | 0.01 | 0.00 | 0.02 | 0.32 | 1.14 | 0.35 | 0.01 | 0.89 | 0.08 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 11.51% | 0.00% | 0.00% | 47.61% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | (0.12) | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | 0.22 | 0.00 | 0.53 | 0.54 | 0.54 | 0.60 | 0.83 | 1.29 | 0.92 |
Capex/Depreciation |
— | 0.00 | — | — | — | (30.43) | 0.00 | (2.90) | (5.92) | 0.00 |
Interest Coverage |
— | (34.21) | — | (318.29) | (31.18) | (264.94) | (1,931.23) | (983.92) | (249.82) | (1,328.30) |
| 192.33% | 137.77% | 0.00% | (774.81%) | (356.08%) | (160.92%) | (181.47%) | (4,408.46%) | (743.10%) | (373.18%) | |
| (248.28%) | (323.97%) | (587.67%) | (266.08%) | (213.54%) | (141.86%) | (145.64%) | (303.88%) | (195.05%) | (262.55%) | |
ROIC |
(1,141.27%) | (1,141.29%) | (2,096,687.50%) | (378.06%) | (738.82%) | 0.00% | 0.00% | 0.00% | (14,412.82%) | (24,352.22%) |
Return on Tangible Assets |
(1,534.40%) | (1,534.40%) | 0.00% | (536.72%) | (250.70%) | (92.59%) | (488.53%) | 383.44% | (128.65%) | (1,196.45%) |
Average Days of Receivables |
— | 0.00 | — | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (23.97) | — | (44.43) | (50.41) | (101.83) | (123.59) | (113.44) | (15.24) | (2.42) |
Cash per Share |
0.00 | 0.98 | — | 1.71 | 35.86 | 213.09 | 71.20 | 5.07 | 8.76 | 0.21 |
Shareholders Equity per Share |
0.00 | 7.27 | 0.00 | 15.56 | 37.41 | 202.30 | 42.18 | (34.96) | 8.80 | 0.22 |
Interest Debt per Share |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 7.27 | 0.00 | 15.56 | 37.41 | 202.30 | 42.18 | (34.96) | 8.80 | 0.22 |
Free Cash Flow |
— | (1.05) | — | (2.35) | (2.71) | (6.72) | (8.92) | (8.42) | (6.87) | (8.07) |
Working Capital |
0.32 | 0.32 | — | 0.82 | 2.01 | 13.25 | 2.97 | (2.77) | 3.54 | 0.42 |
Capital Expenditures |
— | — | — | — | — | (0.11) | — | (0.15) | (0.30) | — |
Net Current Asset Value |
0.32 | 0.32 | — | 0.82 | 2.01 | 13.25 | 2.97 | (2.77) | 3.54 | 0.42 |
| Other line items | ||||||||||
Quick Ratio |
0.04 | 0.04 | — | 0.09 | 2.14 | 12.07 | 1.79 | 0.12 | 6.22 | 0.53 |
Depreciation/Fixed assets |
— | 0.00 | — | — | — | 0.03 | 0.29 | 0.29 | 0.12 | 0.35 |
Cash ROIC |
0.00% | (290.74%) | 0.00% | (257.21%) | (63.40%) | (24.51%) | (109.00%) | 438.97% | (86.75%) | (558.75%) |
Accounts Receivable Turnover |
— | 0.00 | — | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (23.97) | — | (44.43) | (50.41) | (100.21) | (123.59) | (111.46) | (14.57) | (2.42) |
Capex per Share |
— | 0.00 | — | 0.00 | 0.00 | (1.61) | 0.00 | (1.98) | (0.67) | 0.00 |
Average Receivables |
— | 0.35 | — | 0.24 | 0.11 | — | — | — | — | — |
Average Payables |
— | 1.02 | — | 1.02 | 0.72 | 0.83 | 2.02 | 2.90 | 1.78 | 0.99 |
Average Assets |
1.96 | 1.50 | 0.75 | 1.66 | 2.36 | 8.71 | 10.22 | 3.27 | 2.62 | 3.34 |
Average Common Equity |
(2.53) | (3.53) | — | 0.57 | 1.42 | 7.68 | 8.20 | 0.23 | 0.69 | 2.35 |
Capex to Sales |
— | — | — | — | — | 0.00 | — | 0.00 | 0.00 | — |
Columns are period end dates